- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00774085
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone (e-STAR)
April 26, 2012 updated by: Janssen Cilag N.V./S.A.
Electronic Schizophrenia Treatment Adherence Registry
The purpose of this study is to assess treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
Study Overview
Detailed Description
This is an observational (study in which patients/participants are observed) and multicentre (at multiple sites) study.
This is one-country arm of a multinational study.
This study consists of 2 years of retrospective (a study in which the patients are identified and then documented backward in time and 2 years of prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study) study periods during which medication utilization review will be done, determining medication usage patterns and outcomes associated with the use of risperidone long acting, in clinical practice.
Usage of risperidone according to label was recommended during the study.
The planned recruitment period will be 6 months.
Retrospective observation will be 2 years for hospitalization history and at least 1 year for medication usage.
Total duration of prospective observation for each patient with a complete follow-up will be 24 months.
Data collection during the follow up period will be scheduled every 3 months ± 2 weeks.
In addition, this study is proposed in Belgium to satisfy the demand from Belgian Reimbursement Authorities to collect clinical data on the impact of risperidone long acting on treatment compliance, number of hospitalizations and potential prevention of relapses.
Also, this data will provide documentation on switch from oral to parenteral treatment.
Data will be pooled from different physicians and/or countries.
The objectives of this study are: collect clinical outcome data at the request of the Belgian Reimbursement Authorities; prospectively assess medication usage patterns to document clinical efficacy and long-term treatment outcomes of risperidone long acting, in a naturalistic setting; collect retrospective data, to compare with risperidone long acting; document reasons for initiating risperidone; collect data on switch of treatment to risperidone long acting.
Study Type
Observational
Enrollment (Actual)
408
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with schizophrenia
Description
Inclusion Criteria:
- Patient who started long-acting injectable risperidone treatment after agreement between doctor and patient
- Ambulatory patient or not chronically full-time hospitalized patient. Full-time hospitalization at the moment of inclusion for maximal 6 months
- The treatment and treated indication according to local label
- Patient had given informed consent in agreement with local legislation
Exclusion Criteria:
- Patient participating in another medication related study, chronically full-time hospitalized patient, who according to the treating physician had no perspective of being discharged within the planned observation period
- Patient suffering from treatment resistant schizophrenia
- Pregnant or breastfeeding females or females with planned pregnancy within two years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with Schizophrenia
Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
|
Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total length of hospitalization from retrospective to prospective period
Time Frame: 48 months
|
Start date, end date of full-time or partial hospitalization will be recorded both in retrospective and prospective study period.
|
48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline to 24 months in Clinical Global Impression (CGI) Scale scores
Time Frame: Baseline, (just before the first injection of long-acting injectable risperidone) to 24 months
|
Patients are rated for overall severity of schizophrenia disorder using the CGI scale (7 point scale) in which 1 = Not Ill and 7 = Extremely Severe.
|
Baseline, (just before the first injection of long-acting injectable risperidone) to 24 months
|
Change from baseline to 24 months in Global Assessment of Functioning (GAF) scores
Time Frame: Baseline to 24 months
|
This GAF scale rates the functioning of the patient on a scale of 1 - 100 where "1 - 10" is "Persistant danger of severely hurting self or others (eg, recurrent violence) OR persistant inability to maintain personal hygiene OR serious suicidal act with clear expectations of death" and "91- 100" is "Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his of her positive qualities.
No symptoms"
|
Baseline to 24 months
|
Change from baseline to 24 months in clinical deterioration
Time Frame: Baseline, in 3-monthly intervals (± 2 weeks) for 24 months and Last visit
|
Clinical deterioration is assessed by evaluating presence or absence of deliberate self injury, suicidal or homicidal ideation, violent behaviour, and increased need in levels of care and increase in CGI by 2 points or more.
The maintenance of treatment effect is documented by the time to significant deterioration of the psychotic condition.
If signs of significant deterioration occurred more than once within each 3 monthly interval, this is recorded.
|
Baseline, in 3-monthly intervals (± 2 weeks) for 24 months and Last visit
|
Change from baseline to 24 months in assessment of remission
Time Frame: Baseline to 24 months
|
Clinical status will be assessed by presence or absence of the following core symptoms: delusions, conceptual disorganization, hallucinatory behavior, mannerisms and posturing, unusual thought content, blunted affect, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation.
Score will be given for each symptom as follows: Score 1: Absent, Minimal, Mild; Score 2: Moderate, Moderately severe, Severe, Extreme.
Symptomatic remission is defined as a clinical status where for each and every of the symptoms prespecified, a score of 1 can be given for duration of 6 months.
|
Baseline to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Janssen-Cilag N.V./S.A., Belgium Clinical Trial, Janssen Cilag N.V./S.A.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2004
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
October 16, 2008
First Submitted That Met QC Criteria
October 16, 2008
First Posted (Estimate)
October 17, 2008
Study Record Updates
Last Update Posted (Estimate)
April 27, 2012
Last Update Submitted That Met QC Criteria
April 26, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR003886
- RISSCH4002 (Other Identifier: Janssen Cilag N.V./S.A., Belgium)
- 2004-002448-93 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on No intervention was given
-
University of StellenboschNational Research Foundation of South AfricaCompletedProprioceptive Disorders | Anterior Knee Pain SyndromeSouth Africa
-
Marmara UniversitySaglik Bilimleri UniversitesiCompletedOral Health in Children With Inflammatory Bowel DiseaseTurkey
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedPulmonary Hypertension | Acute Myocardial InfarctionChina
-
Firat UniversityCompletedEnvironmental-Pollution-Related ConditionTurkey
-
Taiwan AIDS Nurse SocietyGlaxoSmithKlineUnknown
-
University of Dublin, Trinity CollegeCompleted
-
Hospital Sao RafaelCompleted
-
Barcelona Institute for Global HealthCompletedPoor Mental Health | Natural Outdoor Environments
-
Centro Hospitalar Tondela-ViseuPortuguese IBD GroupCompletedInflammatory Bowel Diseases | Coagulation Disorder | ThromboembolismPortugal
-
Marmara UniversityCompletedHyperlipidemia, Periodontal Disease